Oxford Immunotec (OXFD) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Grand Canyon Education places CFO on leave amid stock trade probe
- Wattmore and Eos Energy strike non-exclusive storage software deal
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Funds sell $44bn in semiconductors on AI concerns
Oxford Immunotec Reports Second Quarter 2018 Financial Results
July 31, 2018 7:00 AM EDTSecond quarter Tuberculosis (TB) revenue growth of 17%, with record TB revenue in the United StatesGross margin improved by 450 basis points compared to prior year period and 630 basis points on a sequential basisLaunch of transformative T-Cell Select product to enable full automation of T-SPOT®.TB test
OXFORD, United Kingdom and MARLBOROUGH, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company, today announced second quarter 2018 financial results.
We are pleased with our second quarter performance, which included a... More
